Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population.

Guella I, Asselta R, Ardissino D, Merlini PA, Peyvandi F, Kathiresan S, Mannucci PM, Tubaro M, Duga S.

J Lipid Res. 2010 Nov;51(11):3342-9. doi: 10.1194/jlr.M010009. Epub 2010 Aug 10.

2.

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.

Langsted A, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Kamstrup PR.

J Clin Endocrinol Metab. 2016 Sep;101(9):3281-7. doi: 10.1210/jc.2016-1206. Epub 2016 May 24.

PMID:
27218270
3.

The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.

Cai G, Zhang B, Shi G, Weng W, Ma C, Song Y, Zhang J.

Lipids Health Dis. 2015 Nov 17;14:149. doi: 10.1186/s12944-015-0154-7.

4.

Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study).

Hallman DM, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS.

Am J Cardiol. 2007 Jul 1;100(1):69-72. Epub 2007 May 11.

PMID:
17599443
5.

Effect of protein convertase subtilisin/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population.

Kostrzewa G, Broda G, Kurjata P, Piotrowski W, Ploski R.

Mol Genet Metab. 2008 Jun;94(2):259-62. doi: 10.1016/j.ymgme.2008.02.003. Epub 2008 Mar 14.

PMID:
18343176
6.

PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.

Saavedra YG, Dufour R, Davignon J, Baass A.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2700-5. doi: 10.1161/ATVBAHA.114.304406. Epub 2014 Oct 2.

7.

The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.

Scartezini M, Hubbart C, Whittall RA, Cooper JA, Neil AH, Humphries SE.

Clin Sci (Lond). 2007 Dec;113(11):435-41.

PMID:
17550346
8.

Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians.

Tsai CW, North KE, Tin A, Haack K, Franceschini N, Saroja Voruganti V, Laston S, Zhang Y, Best LG, MacCluer JW, Beaty TH, Navas-Acien A, Kao WH, Howard BV.

J Clin Endocrinol Metab. 2015 Feb;100(2):E345-9. doi: 10.1210/jc.2014-3340. Epub 2014 Nov 20.

9.

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.

Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A.

J Am Coll Cardiol. 2010 Jun 22;55(25):2833-42. doi: 10.1016/j.jacc.2010.02.044. Review.

10.

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH.

N Engl J Med. 2006 Mar 23;354(12):1264-72.

11.

Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.

Anderson JM, Cerda A, Hirata MH, Rodrigues AC, Dorea EL, Bernik MM, Bertolami MC, Faludi AA, Hirata RD.

J Clin Lipidol. 2014 May-Jun;8(3):256-64. doi: 10.1016/j.jacl.2014.02.008. Epub 2014 Mar 5.

PMID:
24793346
12.

Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study.

Benn M, Tybjærg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG.

J Natl Cancer Inst. 2011 Mar 16;103(6):508-19. doi: 10.1093/jnci/djr008. Epub 2011 Feb 1.

PMID:
21285406
13.

Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.

Polisecki E, Peter I, Robertson M, McMahon AD, Ford I, Packard C, Shepherd J, Jukema JW, Blauw GJ, Westendorp RG, de Craen AJ, Trompet S, Buckley BM, Murphy MB, Ordovas JM, Schaefer EJ; PROSPER Study Group.

Atherosclerosis. 2008 Sep;200(1):95-101. doi: 10.1016/j.atherosclerosis.2007.12.005. Epub 2008 Feb 8.

14.

The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.

Aung LH, Yin RX, Miao L, Hu XJ, Yan TT, Cao XL, Wu DF, Li Q, Pan SL, Wu JZ.

Lipids Health Dis. 2011 Jan 13;10:5. doi: 10.1186/1476-511X-10-5.

15.

Combined PCSK9 and APOE polymorphisms are genetic risk factors associated with elevated plasma lipid levels in a Thai population.

Jeenduang N, Porntadavity S, Wanmasae S.

Lipids. 2015 Jun;50(6):543-53. doi: 10.1007/s11745-015-4017-9. Epub 2015 Apr 22.

PMID:
25899039
16.

Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study.

Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E, Liu K.

Circ Cardiovasc Genet. 2009 Aug;2(4):354-61. doi: 10.1161/CIRCGENETICS.108.828467. Epub 2009 Jun 10.

17.

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, Hobbs HH.

Am J Hum Genet. 2006 Mar;78(3):410-22. Epub 2006 Jan 20.

18.

Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.

Chernogubova E, Strawbridge R, Mahdessian H, Mälarstig A, Krapivner S, Gigante B, Hellénius ML, de Faire U, Franco-Cereceda A, Syvänen AC, Troutt JS, Konrad RJ, Eriksson P, Hamsten A, van 't Hooft FM.

Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1526-34. doi: 10.1161/ATVBAHA.111.240549. Epub 2012 Mar 29.

19.

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.

Mayne J, Ooi TC, Raymond A, Cousins M, Bernier L, Dewpura T, Sirois F, Mbikay M, Davignon J, Chrétien M.

Lipids Health Dis. 2013 May 10;12:70. doi: 10.1186/1476-511X-12-70.

20.

The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan.

Hsu LA, Teng MS, Ko YL, Chang CJ, Wu S, Wang CL, Hu CF.

Clin Chem Lab Med. 2009;47(2):154-8. doi: 10.1515/CCLM.2009.032.

PMID:
19191720

Supplemental Content

Support Center